Effects of Buprenorphine Maintenance Dose on μ-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
The clinical effectiveness of opioid maintenance for heroin dependence is believed to result from a medication's ability to decrease mu-opioid receptor (muOR) availability thereby replacing agonist effects, alleviating withdrawal symptoms and attenuating heroin effects. We empirically tested this hypothesis in five heroin-dependent volunteers who were successively maintained on 32, 16, 2, and 0 mg daily buprenorphine (BUP) tablet doses. We predicted and confirmed that higher BUP doses would decrease in vivo muOR availability (measured with PET and [(11)C]carfentanil), increase plasma levels of BUP and its metabolite nor-BUP, and decrease withdrawal symptoms and hydromorphone (HYD) responses. Relative to placebo, BUP significantly decreased mean (+/-SEM) whole-brain muOR availability 41+/-8, 80+/-2, and 84+/-2% at 2, 16, and 32 mg, respectively. Regions of interest (ROIs) (prefrontal cortex, anterior cingulate, thalamus, amygdala, nucleus accumbens, caudate) showed similar dose-dependent effects. Changes in muOR availability varied across ROIs (prefrontal cortex, 47% vs amygdala, 27%) at BUP 2 mg, but were more homogeneous across ROIs at BUP 32 mg (94-98%; except thalamus, 88%). Relative to placebo (0 ng/ml), peak plasma levels of BUP and nor-BUP were comparable and dose-dependent (0.5-1, 5-6, and 13-14 ng/ml at 2, 16, and 32 mg, respectively). muOR availability decreases were negatively correlated with BUP plasma level and positively correlated with questionnaire-based opioid withdrawal symptoms and attenuation of HYD symptoms. These findings suggest that high-dose BUP maintenance produces near-maximal muOR occupation, muOR availability correlates well with plasma levels, and BUP-related opioid symptoms and antagonist blockade exhibit concentration-effect relationships.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There was a single study by Greenwald et al. 17 (as reported in Greenwald et al. 18 ) that reported occupancy data for mu-opioid occupancy for buprenorphine.”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [17]
In the citing paper
“We derived a curve of best fit for buprenorphine from dose-occupancy data in Greenwald et al. 17 (as reported in Greenwald et al. 18 ) where occupancy was measured 4 h after 12 days of maintenance treatment with doses ranging from 1 to 32 mg (Figure 2 and Table 3).”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [17]
In the citing paper
“This was corroborated by Greenwald et al. (117) who found that higher buprenorphine doses (up to 32 mg given as a tablet*) led to increased plasma buprenorphine levels, decreased μ-opioid receptor availability, and decreased withdrawal symptoms.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [117]
In the citing paper
“In the same study, heroin craving was found to be significantly correlated with μ-opioid receptor availability and negatively correlated with buprenorphine plasma levels.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [117]
Citations
Cites
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688 · cited 1×
“The global binding potential value was calculated using SPM99 (Friston et al, 1995) as the average value across all brain voxels.”
MethodMcLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514
New Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“An experienced clinician administered a semistructured interview (SCID-IV; First et al, 1996), and opioid dependence severity was determined using the Addiction Severity Index (McLellan et al, 1985a, b).”
MethodMintun, M. A., Raichle, M. E., Kilbourn, M. R., Wooten, G. F., & Welch, M. J. (1984) · Annals of Neurology · doi:10.1002/ana.410150302 · Cited by 955
Self-citationJasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 1×
“Earlier human laboratory studies showed that administration of subcutaneous BUP (Jasinski et al, 1978; Mello et al, 1982) or sublingual BUP liquid (Bickel et al, 1988; Rosen et al, 1994; Walsh et al, 1995) could attenuate the reinforcing, subjective, and physiological effects of mOR agonists.”
BackgroundA Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623 · cited 2×
“Numerous clinical trials support the safety and efficacy of BUP (eg Fudala et al, 1990; Johnson et al, 1995, 2000; Ling et al, 1998), which led to US Food and Drug Administration approval in October 2002 of two sublingual tablet formulations (BUP alone (Subutext) or combined with naloxone using a 4…”
BackgroundMethodAGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528
Meyer, C. R., Boes, J. L., Kim, B., Bland, P. H., Zasadny, K. R., Kison, P. V., Koral, K., Frey, K. A., & Wahl, R. L. (1997) · Medical Image Analysis · doi:10.1016/s1361-8415(97)85010-4 · Cited by 460
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402 · cited 2×
“Numerous clinical trials support the safety and efficacy of BUP (eg Fudala et al, 1990; Johnson et al, 1995, 2000; Ling et al, 1998), which led to US Food and Drug Administration approval in October 2002 of two sublingual tablet formulations (BUP alone (Subutext) or combined with naloxone using a 4…”
BackgroundMethod
Research works printed but not linked: 2
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis Disorders—Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, NY State Psychiatric Institute: New York.
- Lewis JW, Rance MJ, Sanger DJ (1983). The pharmacology and abuse potential of buprenorphine: a new antagonist analgesic. In: Mello NK (ed). Advances in Substance Abuse Vol. 3 JAI Press: Greenwich, 103–154.
Cited by
Maintenance Medication for Opiate Addiction: The Foundation of Recovery
Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461
Hser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455
Hedonic Hot Spots in the Brain
Peciña, S., Smith, K. S., & Berridge, K. C. (2006) · The Neuroscientist · doi:10.1177/1073858406293154 · Cited by 441
Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments
Kreek, M. J., Bart, G., Lilly, C., Laforge, K. S., & Nielsen, D. A. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.1 · Cited by 391
Buprenorphine: Clinical Pharmacokinetics in the Treatment of Opioid Dependence
Elkader, A., & Sproule, B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544070-00001 · Cited by 335
Medication Treatment of Opioid Use Disorder
Bell, J., & Strang, J. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.06.020 · Cited by 328
Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile
Pergolizzi, J., Aloisi, A. M., Dahan, A., Filitz, J., Langford, R., Likar, R., Mercadante, S., Morlion, B., Raffa, R. B., Sabatowski, R., et al. (2010) · Pain Practice · doi:10.1111/j.1533-2500.2010.00378.x · Cited by 284
Response of the μ-opioid system to social rejection and acceptance
Hsu, D. T., Sanford, B. J., Meyers, K. K., Love, T. M., Hazlett, K. E., Wang, H., Ni, L., Walker, S. J., Mickey, B. J., Korycinski, S. T., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.96 · Cited by 225
Self-citationImaging of opioid receptors in the central nervous system
Henriksen, G., & Willoch, F. (2008) · Brain · doi:10.1093/brain/awm255 · Cited by 214
Witkin, J. M., Statnick, M. A., Rorick-Kehn, L. M., Pintar, J. E., Ansonoff, M., Chen, Y., Tucker, R. C., & Ciccocioppo, R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.011 · Cited by 194
“Extrapolating from human PET imaging studies with [11C]-carfentanil it is reasonable to assert that at 16 mg/day buprenorphine reach a full occupation of mu opioid receptors (Greenwald et al., 2003).”
MethodMacDonald, K., & Feifel, D. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00035 · Cited by 181
Twelve Reasons for Considering Buprenorphine as a Frontline Analgesic in the Management of Pain
Davis, M. P. (2012) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2012.05.002 · Cited by 179
Greenwald, M. K., Comer, S. D., & Fiellin, D. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.07.035 · Cited by 174
“BUP maintenance dose is inversely related to μOR availability in opioid-dependent volunteers; however, it is not reasonable to compare receptor availability estimates from Comer et al. (2005) and Greenwald et al. (2003) due to methodological differences.”
BackgroundMethodResultInfluentialSelf-citationRibeiro, S. C. M., Kennedy, S. E., Smith, Y. R., Stohler, C. S., & Zubieta, J. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.08.011 · Cited by 167
Self-citationKohan, L. R., Potru, S., Barreveld, A. M., Sprintz, M., Lane, O. P., Aryal, A., Emerick, T. D., Dopp, A., Chhay, S., & Viscusi, E. R. (2021) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2021-103007 · Cited by 164
Impaired decision-making in opiate-dependent subjects: Effect of pharmacological therapies
Pirastu, R., Fais, R. S., Messina, M., Bini, V., Spiga, S., Falconieri, D., & Diana, M. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.11.008 · Cited by 163
Buprenorphine/Naloxone: A Review of its Use in the Treatment of Opioid Dependence
Orman, J. S., & Keating, G. M. (2009) · Drugs · doi:10.2165/00003495-200969050-00006 · Cited by 163
High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
Herring, A. A., Vosooghi, A. A., Luftig, J., Anderson, E. S., Zhao, X., Dziura, J., Hawk, K. F., McCormack, R. P., Saxon, A., & D’Onofrio, G. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.17128 · Cited by 159
Smith, S. M., Dworkin, R. H., Turk, D. C., Baron, R., Polydefkis, M., Tracey, I., Borsook, D., Edwards, R. R., Harris, R. E., Wager, T. D., et al. (2017) · The Journal of Pain · doi:10.1016/j.jpain.2017.02.429 · Cited by 151
Opioid reward ‘liking’ and ‘wanting’ in the nucleus accumbens
Peciña, S. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.04.006 · Cited by 158
The Development, Past Achievements, and Future Directions of Brain PET
Jones, T., & Rabiner, E. A. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.20 · Cited by 156
Ray, R., Ruparel, K., Newberg, A., Wileyto, E. P., Loughead, J. W., Divgi, C., Blendy, J. A., Logan, J., Zubieta, J.-K., & Lerman, C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018699108 · Cited by 137
Self-citationTo Stop or Not, That Is the Question: Acute Pain Management for the Patient on Chronic Buprenorphine
Anderson, T. A., Quaye, A., Ward, E. N., Wilens, T. E., Hilliard, P. E., & Brummett, C. M. (2017) · Anesthesiology · doi:10.1097/aln.0000000000001633 · Cited by 144
Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus
Dematteis, M., Auriacombe, M., D’Agnone, O., Somaini, L., Szerman, N., Littlewood, R., Alam, F., Alho, H., Benyamina, A., Bobes, J., et al. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1409722 · Cited by 141
Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice
Kakko, J., Alho, H., Baldacchino, A., Molina, R., Nava, F. A., & Shaya, G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00592 · Cited by 140
Target site occupancy: Emerging generalizations from clinical and preclinical studies
Grimwood, S., & Hartig, P. R. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.002 · Cited by 139
Understanding buprenorphine for use in chronic pain: expert opinion
Webster, L., Gudin, J., Raffa, R. B., Kuchera, J., Rauck, R., Fudin, J., Adler, J., & Mallick-Searle, T. (2020) · Pain Medicine · doi:10.1093/pm/pnz356 · Cited by 130
Current status of opioid addiction treatment and related preclinical research
Kreek, M. J., Reed, B., & Butelman, E. R. (2019) · Science Advances · doi:10.1126/sciadv.aax9140 · Cited by 128
Hedonic and motivational roles of opioids in food reward: Implications for overeating disorders
Peciña, S., & Smith, K. S. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.05.016 · Cited by 127
Greenwald, M., Johanson, C.-E., Bueller, J., Chang, Y., Moody, D. E., Kilbourn, M., Koeppe, R., & Zubieta, J.-K. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.043 · Cited by 124
Self-citationUnderstanding the use of diverted buprenorphine
Cicero, T. J., Ellis, M. S., & Chilcoat, H. D. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.09.007 · Cited by 117
Klaire, S. S., Zivanovic, R., Barbic, S. P., Sandhu, R., Mathew, N., & Azar, P. (2019) · American Journal on Addictions · doi:10.1111/ajad.12869 · Cited by 108
Management of chronic pain in the elderly: focus on transdermal buprenorphine
Vadivelu, N., & Hines, R. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s1880 · Cited by 104
The clinical analgesic efficacy of buprenorphine
Raffa, R. B., Haidery, M., Huang, H.-M., Kalladeen, K., Lockstein, D. E., Ono, H., Shope, M. J., Sowunmi, O. A., Tran, J. K., & Pergolizzi, J. V. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12196 · Cited by 105
“This is consistent with PET scans of human brains showing that at clinically analgesic doses of buprenorphine, there remains a reserve of unoccupied l-opioid receptors.(41) Based on these results, buprenorphine has full analgesic efficacy in clinical pain practice.”
BackgroundMacintyre, P. E., Russell, R., Usher, K. A. N., Gaughwin, M. D., & Huxtable, C. A. (2013) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1304100212 · Cited by 105
Harrison, T. K., Kornfeld, H., Aggarwal, A. K., & Lembke, A. (2018) · Anesthesiology Clinics · doi:10.1016/j.anclin.2018.04.002 · Cited by 99
Comer, S. D., Walker, E. A., & Collins, E. D. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0023-6 · Cited by 98
Chronic and Acute Pain and Pain Management for Patients in Methadone Maintenance Treatment
Eyler, E. C. H. (2013) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2013.00308.x · Cited by 82
The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
Aquino, J. P. D., Parida, S., & Sofuoglu, M. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01032-7 · Cited by 95
Factors contributing to the rise of buprenorphine misuse: 2008–2013
Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.06.005 · Cited by 95
Sorge, R. E., Rajabi, H., & Stewart, J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300712 · Cited by 90
Neri, S., Bruno, C. M., Pulvirenti, D., Malaguarnera, M., Italiano, C., Mauceri, B., Abate, G., Cilio, D., Calvagno, S., Tsami, A., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2239-x · Cited by 90
WALSH, S. L., Comer, S. D., Lofwall, M. R., Vince, B. D., Levy‐Cooperman, N., Kelsh, D., Coe, M. A., Jones, J. D., Nuzzo, P. A., Tiberg, F., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1874 · Cited by 87
Perioperative Management of Buprenorphine: Solving the Conundrum
Quaye, A., & Zhang, Y. (2018) · Pain Medicine · doi:10.1093/pm/pny217 · Cited by 86
Metabolism and Disposition of Prescription Opioids: A Review.
DePriest, A. Z., Puet, B. L., Holt, A. C., Roberts, A., & Cone, E. J. (2015) · PubMed · Cited by 85
Lembke, A., Ottestad, E., & Schmiesing, C. A. (2018) · Pain Medicine · doi:10.1093/pm/pny019 · Cited by 85
Evidence on Buprenorphine Dose Limits: A Review
Grande, L. A., Cundiff, D., Greenwald, M. K., Murray, M., Wright, T. E., & Martin, S. A. (2023) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001189 · Cited by 80
Self-citationHuang, W. C., Moody, D. E., & McCance‐Katz, E. F. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000197094.92559.b4 · Cited by 80
Self-citationJordan, C. J., Cao, J., Newman, A. H., & Xi, Z. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.04.015 · Cited by 79
Burns, J. A., Kroll, D. S., Feldman, D. E., Liu, C. K., Manza, P., Wiers, C. E., Volkow, N. D., & Wang, G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00626 · Cited by 79
Mendelson, J., Flower, K., Pletcher, M. J., & Galloway, G. P. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0013637 · Cited by 71
Buresh, M., Ratner, J., Zgierska, A. E., Gordin, V., & Alvanzo, A. A. H. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06115-3 · Cited by 78
Imaging Drugs with and without Clinical Analgesic Efficacy
Upadhyay, J., Anderson, J., Schwarz, A. J., Coimbra, A., Baumgartner, R., Pendse, G., George, E., Nutile, L. M., Wallin, D. J., Bishop, J. H., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.156 · Cited by 76
Medication-assisted treatment for opioid addiction: Methadone and buprenorphine
Saxon, A. J., Hser, Y.-I., Woody, G., & Ling, W. (2013) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2013.09.037 · Cited by 69
Ide, S., Minami, M., Satoh, M., Uhl, G. R., Sora, I., & Ikeda, K. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300463 · Cited by 76
Lever, J. (2006) · Current Pharmaceutical Design · doi:10.2174/138161207779313821 · Cited by 74
Heidbreder, C. A., Fudala, P. J., & Greenwald, M. K. (2023) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2023.100133 · Cited by 73
Self-citationSeldén, T., Ahlner, J., Druid, H., & Kronstrand, R. (2012) · Forensic Science International · doi:10.1016/j.forsciint.2012.03.016 · Cited by 73
The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus
Pergolizzi, J. V., Mercadante, S., Echaburu, A. V., den Eynden, B. V., Fragoso, R. M., Mordarski, S., Lybaert, W., Beniak, J., Orońska, A., & Sláma, O. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902920731 · Cited by 73
Melichar, J. K., Hume, S. P., Williams, T. M., Daglish, M. R. C., Taylor, L. G., Ahmad, R., Malizia, A. L., Brooks, D. J., Myles, J. S., Lingford-Hughes, A., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.072686 · Cited by 71
Davis, M. P. (2005) · Supportive Care in Cancer · doi:10.1007/s00520-005-0849-9 · Cited by 71
Borsook, D., Hargreaves, R. J., & Becerra, L. R. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.584529 · Cited by 70
An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy
Caritis, S. N., Bastian, J. R., Zhang, H., Kalluri, H. V., English, D., England, M. J., Bobby, S., & Venkataramanan, R. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.029 · Cited by 70
Goel, A., Azargive, S., Weissman, J. S., Shanthanna, H., Hanlon, J. G., Samman, B., Dominicis, M., Ladha, K. S., Lamba, W., Duggan, S., et al. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.03.044 · Cited by 66
A Neuropharmacological Model to Explain Buprenorphine Induction Challenges
Greenwald, M. K., Herring, A. A., Perrone, J., Nelson, L. S., & Azar, P. (2022) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2022.05.032 · Cited by 65
Self-citationLandau, R. (2019) · International Journal of Obstetric Anesthesia · doi:10.1016/j.ijoa.2019.01.011 · Cited by 61
Comer, S. D., Bickel, W. K., Yi, R., de Wit, H., Higgins, S. T., Wenger, G. R., Johanson, C., & Kreek, M. J. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833bb9f8 · Cited by 60
Self-citationChadwick, A. L., Frazier, A., Khan, T. W., & Young, E. E. (2021) · Journal of Pain Research · doi:10.2147/jpr.s320863 · Cited by 60
Ding, Z., & Raffa, R. B. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00209.x · Cited by 61
Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine
Upadhyay, J., Anderson, J., Baumgartner, R., Coimbra, A., Schwarz, A. J., Pendse, G., Wallin, D. J., Nutile, L. M., Bishop, J. H., George, E., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.034 · Cited by 59
Warner, N. S., Warner, M. A., Cunningham, J. L., Gazelka, H. M., Hooten, W. M., Kolla, B. P., & Warner, D. O. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.10.007 · Cited by 57
Imaging the Neurochemistry of Alcohol and Substance Abuse
Martínez, D., Kim, J., Krystal, J. H., & Abi‐Dargham, A. (2007) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2007.07.004 · Cited by 57
Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio
Molfenter, T. D., Sherbeck, C., Zehner, M. E., Quanbeck, A., McCarty, D. W., Kim, J.-S., & Starr, S. (2015) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-015-0009-2 · Cited by 56
An injection depot formulation of buprenorphine: extended biodelivery and effects
Sigmon, S. C., Moody, D. E., Nuwayser, E. S., & Bigelow, G. E. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01348.x · Cited by 55
Self-citationGreenwald, M. K., Lundahl, L. H., & Steinmiller, C. L. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2868-9 · Cited by 53
Self-citationBuprenorphine in Postoperative Pain Management
Vadivelu, N., & Anwar, M. A. F. (2010) · Anesthesiology Clinics · doi:10.1016/j.anclin.2010.08.015 · Cited by 54
Jones, A. K., Ngaimisi, E., Gopalakrishnan, M., Young, M. A., & Laffont, C. M. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00957-0 · Cited by 53
Medication Pain Management in the Elderly: Unique and Underutilized Analgesic Treatment Options
Atkinson, T. J., Fudin, J., Pandula, A., & Mirza, M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.008 · Cited by 52
Laffont, C. M., Goméni, R., Heidbreder, C. A., Jones, J. P., & Nasser, A. F. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.665 · Cited by 52
Addiction: the clinical interface
Nutt, D. J., & Lingford-Hughes, A. R. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.101 · Cited by 52
Buprenorphine/Naloxone for opioid dependence: clinical practice guideline.
Handford, C. D., Kahan, M., Srivastava, A., Cirone, S., & Palda, V. A. (2011) · Cited by 51
Weimer, M. B., Morford, K. L., & Donroe, J. H. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00267-x · Cited by 49
Foster, B., Twycross, R., Mihalyo, M., & Wilcock, A. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.03.001 · Cited by 49
Adherence to buprenorphine: An analysis of prescription drug monitoring program data
Pizzicato, L. N., Hom, J. K., Sun, M., Johnson, C. C., & Viner, K. M. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108317 · Cited by 47
Nasser, A. F., Heidbreder, C. A., Goméni, R., Fudala, P. J., Zheng, B., & Greenwald, M. K. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0155-0 · Cited by 47
Self-citationKapil, R. P., Cipriano, A., Friedman, K., Michels, G., Shet, M. S., Colucci, S. V., Apseloff, G., Kitzmiller, J., & Harris, S. (2012) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2012.06.014 · Cited by 47
Modeling of PET data in CNS drug discovery and development
Varnäs, K., Varrone, A., & Farde, L. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9320-6 · Cited by 45
Boyett, B., Wiest, K. L., McLeod, L., Nelson, L. M., Bickel, W. K., Learned, S. M., Heidbreder, C. A., Fudala, P. J., Moigne, A. L., & Zhao, Y. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109057 · Cited by 45
Disparities in Addiction Treatment
Jackson, D. S., Tiako, M. J. N., & Jordan, A. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.08.008 · Cited by 47
Messinis, L., Lyros, E., Andrian, V., Katsakiori, P. F., Panagis, G., Georgiou, V. L., & Papathanasopoulos, P. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1050 · Cited by 45
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Vierke, C., Marxen, B., Böettcher, M., Hiemke, C., & Havemann‐Reinecke, U. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01091-0 · Cited by 43
Treating Chronic Pain with Buprenorphine—The Practical Guide
Case, A. A., Kullgren, J. G., Anwar, S., Pedraza, S. L., & Davis, M. P. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00910-8 · Cited by 43
Neuropharmacology of addiction and how it informs treatment
Lingford-Hughes, A. R., Watson, B. J., Kalk, N. J., & Reid, A. G. (2010) · British Medical Bulletin · doi:10.1093/bmb/ldq032 · Cited by 43
Hjelmström, P., Nordbeck, E. B., & Tiberg, F. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1706552 · Cited by 42
Tompkins, D. A., Smith, M. T., Mintzer, M. Z., Campbell, C. M., & Strain, E. C. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.209478 · Cited by 41
Blanco-Gandía, M. C., & Rodríguez‐Arias, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.007 · Cited by 41
News and views on in-vivo imaging of neurotransmission using PET and MRI
Sander, C. Y. M., & Hesse, S. (2017) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.17.03019-9 · Cited by 41
Rosas, M. E. R., Lofwall, M. R., Strain, E. C., Siluk, D., & Wainer, I. W. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.11.025 · Cited by 41
Raffa, R. B., & Ding, Z. (2007) · Acute Pain · doi:10.1016/j.acpain.2007.07.002 · Cited by 40
Shah, M. D., Yates, D., Hunt, J., & Murrell, J. C. (2018) · Journal of Small Animal Practice · doi:10.1111/jsap.12859 · Cited by 40
Metadata
- Authors
- Greenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K.
- Affiliations
- Wayne State University (US)
- University of Utah (US)
- University of Michigan (US)
- Corresponding author
- Greenwald, Mark K
- Venue
- Neuropsychopharmacology
- Published
- 2003-05-30
- Volume
- 28
- Issue
- 11
- Pages
- 2000-2009
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2040327352
- Cited by
- 320
- References
- 44
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 16 · 2023: 20 · 2022: 19 · 2021: 23 · 2020: 20 · 2019: 20 · 2018: 11 · 2017: 14 · 2016: 3 · 2015: 12 · 2014: 11 · 2013: 22 · 2012: 14
- FWCI
- 10.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wayne State University
- U.S. Public Health Service (DA00254)
- National Institute on Drug Abuse (R01 DA 10100, P50DA000254, DA-00254, R01DA010100, P50 DA00254, P01DA000254)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- buprenorphine, heroin addiction, opioid maintenance treatment, dose-response relationship, opioid withdrawal symptoms
- MeSH terms
- Adult, Analysis of Variance, Buprenorphine, Dose-Response Relationship, Drug, Female, Heroin Dependence, Humans, Male, Middle Aged, Narcotic Antagonists, Tomography, Emission-Computed, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.